Effets secondaires des inhibiteurs de checkpoint utilisés dans le traitement des mélanomes et d’autres cancers

Jacquin-Porretaz, C.; Nardin, Charlée; Puzenat, E.; Roche-Kubler, B.; Aubin, F.; Schillo, F.; Meillet, L.; Borot, Sophie; Vuitton, Lucine; Koch, Stéphane; Westeel, Virginie; Jacoulet, P.; Cervoni, Jean Paul; Martino, Vincent Di; Chauchet, Adrien; Wendling, Daniel; Badoz, Marc; Ducloux, Didier; Tatu, Laurent; Delbosc, B.

doi:10.1016/j.lpm.2017.05.032

Cited by 5 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…in other organs, and diarrhea in the gastrointestinal tract [4]. These blocking antibodies target the immune checkpoint molecules CTLA-4 and PD-1 and have been approved for the treatment of metastatic melanoma in 2011, non-smallcell lung cancers, and metastatic renal cancer [5].…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis

Khan

Katona

2021

Cureus

View full text Add to dashboard Cite

Checkpoint inhibitors (CPIs) are a new class of drugs that have changed the treatment and prognosis of several malignancies, even in their advanced stages. These drugs have increased patient survival rates. CPIs stimulate the immune system and include cytotoxic T-lymphocyte antigen-4 inhibitors (ipilimumab), programmed cell death inhibitors such as pembrolizumab, nivolumab, and avelumab, and programmed cell death protein ligand-1 inhibitors such as atezolizumab. Herein, we present a case of CPI-induced colitis in a 45-year-old woman with a history of melanoma. The melanoma was BRAF-positive with a V600 mutation. She had metastasis to the brain and the right 10th rib, which underwent surgery and radiation treatment, respectively. She was treated with nivolumab and denosumab. The patient presented with chronic watery diarrhea. Biopsy revealed lymphocytic colitis-like changes in the colon and terminal ileum. Thus, given the history of CPIs, a diagnosis of CPIS-induced colitis was made.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis

Khan

Katona

2021

Cureus

View full text Add to dashboard Cite

show abstract

Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

Carlet¹,

Dalle²,

Leccia³

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Acceptabilité et efficacité des immunothérapies dans le traitement du mélanome

Valnet-Rabier¹,

Marcucci²,

Limat

et al. 2019

Therapies

View full text Add to dashboard Cite

The immunotherapies known as "inhibitors of checkpoint" (ICP) are monoclonal antibodies used since 2010 and have dramatically modified the management of the advanced or metastatic melanomas. By reactivating the anti-tumoral immune response, these antibodies can activate the immune system in all the tissues with a risk to induce immune related adverse events (IrAE). Thus, the adverse effect's profile of ICP is considered as very different from that usually associated with conventional chemotherapies. The objectives of our retrospective monocentric study were the evaluation of the real life's safety and efficiency of the ipilimumab and the pembrolizumab in patients with an advanced melanoma. Seventy-two patients treated by ipilimumab and\or pembrolizumab between August 1st, 2008 and December 31st, 2016 were investigated. The main IrAE occurring involved the gastro- intestinal, skin, and the endocrine systems. The average onset time of IrAE was 39, 104 and 68 days, respectively and their respective duration was of 67, 50 and 111 days. There were 13 events of grade III and IV along with one death. The overall survival was 5 months for the patients treated in monotherapy with ipilimumab, and 14 months for those treated by pembrolizumab. Our real life's study tends to confirm the current safety profile of ICP treatment. Moreover and according to our analyses, the drug sequence seems to have a global survival impact.

show abstract

Effets secondaires des inhibiteurs de checkpoint utilisés dans le traitement des mélanomes et d’autres cancers

Cited by 5 publications

References 29 publications

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis

Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

Acceptabilité et efficacité des immunothérapies dans le traitement du mélanome

Contact Info

Product

Resources

About